TEPEZZA Market Size Set for Continued Growth With Expanding Thyroid Eye Disease Treatment Adoption

The TEPEZZA market is expected to experience continued growth as the therapy maintains strong adoption in Thyroid Eye Disease (TED) and expands its commercial reach across major markets. TEPEZZA remains the first and only FDA-approved therapy specifically indicated for TED, including both active and chronic disease. Since its approval in 2020, the treatment has changed the management of TED by targeting insulin-like growth factor-1 receptor (IGF-1R), a key factor involved in the disease.

TEPEZZA has demonstrated significant reductions in proptosis and diplopia, two major manifestations of TED. Its clinical differentiation, established treatment profile, and continued physician adoption have supported sustained patient demand. Since launch, more than 25,000 patients worldwide have received TEPEZZA treatment.

The commercial performance of TEPEZZA also remains significant. In Q4 2025, TEPEZZA generated US$457 million in quarterly sales, while full-year sales increased 3% year-over-year despite temporary inventory fluctuations. Amgen also reported continued volume growth, reflecting sustained physician adoption and demand expansion.

To Know in detail about the TEPEZZA market outlook, sales forecast, treatment scenario and competitive landscape, Click here; TEPEZZA Market Forecast

Some of the Key Facts of the TEPEZZA Market Report:

• TEPEZZA Approval: TEPEZZA became the first FDA-approved therapy for Thyroid Eye Disease in 2020.
• Mechanism of Action: TEPEZZA targets and inhibits insulin-like growth factor-1 receptor (IGF-1R), which is overexpressed in orbital fibroblasts and immune cells involved in TED pathogenesis.
• Patient Reach: More than 25,000 patients worldwide have received TEPEZZA treatment since its launch.
• Q4 2025 Sales: TEPEZZA generated US$457 million in quarterly sales during Q4 2025.
• Subcutaneous Development: In April 2026, Amgen announced positive Phase III results for a subcutaneous on-body injector formulation of TEPEZZA.
• Japan Approval: TEPEZZA received approval in Japan in 2024 and became the first approved TED therapy in Asia.
• Forecast Coverage: The TEPEZZA market report provides sales forecasts and market assessments through 2034 across the 7MM.

TEPEZZA Overview

TEPEZZA is a fully human monoclonal antibody developed by Amgen and originally by Horizon Therapeutics for the treatment of thyroid eye disease, a rare and debilitating autoimmune condition associated with Graves’ disease. Administered as an intravenous infusion, TEPEZZA specifically targets and inhibits IGF-1R.

By blocking IGF-1R signaling, TEPEZZA reduces inflammation, tissue expansion, fibrosis, and proptosis. The therapy can improve vision-related symptoms, diplopia, pain, and quality of life. TEPEZZA became the first FDA-approved therapy for TED in 2020 after pivotal Phase III OPTIC studies demonstrated significant reductions in proptosis and clinical activity scores compared with placebo.

The therapy has demonstrated durable responses in both active and chronic TED. However, adverse events including muscle spasms, hearing impairment, hyperglycemia, and infusion reactions have been reported.

Get a Free sample for the TEPEZZA Market Forecast, Size & Share Analysis Report: TEPEZZA Market Forecast

Key Trends in the TEPEZZA Market:

• First and only approved TED therapy: TEPEZZA remains the first and only FDA-approved therapy specifically indicated for Thyroid Eye Disease, including active and chronic disease.
• Strong commercial performance: TEPEZZA generated US$457 million in quarterly sales in Q4 2025, with full-year sales increasing 3% year-over-year.
• Growing patient adoption: More than 25,000 patients worldwide have received TEPEZZA since launch.
• Subcutaneous formulation development: Positive Phase III results for a subcutaneous on-body injector formulation could improve convenience compared with the current intravenous infusion regimen.
• International expansion: TEPEZZA received approval in Japan in 2024, creating additional opportunities across international markets.
• High unmet medical need: TED can cause vision-threatening complications, facial disfigurement, pain, and substantial quality-of-life impairment, supporting continued demand for effective treatment.

TEPEZZA Recent Developments:

In April 2026, Amgen announced positive topline results from a Phase III trial evaluating TEPEZZA administered through a subcutaneous injection using an on-body injector in participants with moderate-to-severe active Thyroid Eye Disease. The study demonstrated a 77% proptosis responder rate, with clinically meaningful reductions exceeding 3 mm.

The subcutaneous on-body injector formulation could improve patient convenience compared with intravenous administration, potentially reducing infusion-center burden and improving accessibility. This lifecycle expansion may support TEPEZZA's continued commercial position as other TED therapies enter development.

TEPEZZA also received approval in Japan in 2024, becoming the first approved TED therapy in Asia. Amgen estimated approximately 25,000–35,000 TED patients in Japan, including active and chronic disease populations.

TEPEZZA Market Assessment and Sales Forecast

The TEPEZZA market report provides a comprehensive assessment of TEPEZZA for approved indications such as Graves ophthalmopathy across the seven major markets. These include the United States, EU4 comprising Germany, France, Italy, and Spain, the United Kingdom, and Japan.

The report provides historical and current TEPEZZA performance along with future market assessments and TEPEZZA sales forecasts through 2034. It also examines TEPEZZA's mechanism of action, dosage and administration, research and development activities, regulatory milestones, and other developmental activities.

Furthermore, the report provides insights into market competitors, emerging therapies, SWOT analysis, analysts' views, and factors driving TEPEZZA sales.

TEPEZZA Drug Uptake and Development Activities

The TEPEZZA market analysis covers the existing use of TEPEZZA in approved indications and evaluates its anticipated performance across the 7MM. The report provides current and forecasted sales data and examines the factors influencing TEPEZZA market performance.

The clinical assessment includes information on TEPEZZA clinical trials for approved indications, including trial interventions, conditions, trial status, and trial start and completion dates. The analysis also covers emerging products and their respective launch timelines, providing insights into the competitive environment.

TEPEZZA Market Potential and Competitive Landscape

The TEPEZZA market report evaluates projected market size for TEPEZZA and its key indications, estimated sales potential, pricing strategies, and reimbursement landscape. It also assesses the number of competing drugs in development and TEPEZZA's market positioning compared with existing treatments.

The competitive intelligence assessment includes TEPEZZA's strengths and weaknesses relative to competitors, pipeline analysis, and the broader competitive landscape. The report also examines emerging products for Graves ophthalmopathy that could create additional competition as late-stage therapies approach potential market entry.

TEPEZZA Regulatory and Commercial Milestones

TEPEZZA's regulatory and commercial development remains an important component of its market outlook. The report covers key regulatory approvals, expected launch timelines, commercial partnerships, licensing deals, and M&A activity.

TEPEZZA's approval in Japan in 2024 represents an important international milestone. In addition, the development of the subcutaneous on-body injector formulation represents a significant lifecycle development that could expand treatment convenience and accessibility.

TEPEZZA Clinical Differentiation

TEPEZZA's clinical differentiation is linked to its targeted mechanism of action and demonstrated efficacy in TED. By inhibiting IGF-1R signaling, TEPEZZA addresses a mechanism involved in TED pathogenesis rather than solely managing symptoms.

The therapy has demonstrated reductions in proptosis and diplopia and has shown durable responses in active and chronic TED. Its unique selling points, efficacy, safety considerations, and clinical profile are evaluated within the TEPEZZA market report.

Scope of the TEPEZZA Market Report

The TEPEZZA market report provides insights into:

• Product Overview: TEPEZZA mechanism of action, description, dosage and administration, and research and development activities in approved indications such as Graves ophthalmopathy.
• Regulatory Assessment: Detailed information on TEPEZZA regulatory milestones and development activities.
• Sales and Pricing: Reported and estimated TEPEZZA sales performance, cost estimates, and regional variations across the United States, Europe, and Japan.
• Patent Information: TEPEZZA patent information, generic entry, and potential impact on costs.
• Market Forecast: Current and forecasted TEPEZZA sales for approved indications through 2034.
• Emerging Therapies: Coverage of late-stage emerging therapies for relevant indications.
• Competitive Intelligence: SWOT analysis and analyst views for TEPEZZA in approved indications.
• Clinical Assessment: Clinical trial information covering interventions, conditions, trial status, and trial timelines.
• Competitive Landscape: Competitors, marketed products, emerging products, and expected launch timelines.

TEPEZZA Market Drivers

• Strong Clinical Differentiation: TEPEZZA's targeted IGF-1R mechanism and demonstrated reductions in proptosis and diplopia support its position in the TED treatment landscape.
• Sustained Patient Demand: More than 25,000 patients worldwide have received TEPEZZA since launch, while continued volume growth has been reported.
• High Unmet Medical Need: TED can result in vision-threatening complications, pain, facial disfigurement, and quality-of-life impairment, creating continued demand for effective treatment options.
• International Expansion: Approval in Japan and potential expansion into additional international markets provide opportunities to increase the addressable patient population.
• Subcutaneous Formulation Opportunity: The positive Phase III results for the subcutaneous on-body injector may improve convenience and reduce the burden associated with intravenous infusion.

TEPEZZA Market Barriers

• Adverse Events: TEPEZZA treatment has been associated with adverse events including muscle spasms, hearing impairment, hyperglycemia, and infusion reactions.
• Infusion Administration: The current intravenous infusion regimen can create treatment and infusion-center burden compared with a potentially more convenient subcutaneous option.
• Emerging Competition: Other emerging products for Graves ophthalmopathy are expected to create additional competition for TEPEZZA as late-stage therapies progress toward potential launches.
• Cost and Pricing Considerations: The report evaluates TEPEZZA cost estimates, pricing trends, reimbursement, and regional variations, which are relevant to its commercial positioning.

TEPEZZA Market Report Highlights

The TEPEZZA market scenario is expected to evolve with continued adoption, increasing prescriptions, broader uptake, international expansion, and lifecycle development. The emergence of additional therapies for Graves ophthalmopathy may also influence the competitive environment.

The TEPEZZA market report provides a detailed description of regulatory milestones, developmental activities, clinical assessments, competitive intelligence, and market positioning. It also evaluates TEPEZZA sales forecasts through 2034 to support strategic decision-making concerning its approved indications.

To know more about TEPEZZA sales forecasts, market positioning, and competitive landscape, visit @ TEPEZZA Market Size and Forecast